Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Learn more about:
Related Clinical Trial
Cardiac Involvement in Wilson’s Disease Oral Health and Wilson’s Disease: SOMAWI Gandouling in the Treatment of Wilson’s Disease International Wilson’s Disease Patient Registry (iWilson Registry) Wilson France Register Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease rTMS in Wilmson Diasease Dysarthria Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Official Title

A Multicenter, Randomized, Controlled, Open-label, Rater-blinded Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Brief Summary

      This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and
      pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson
      disease (WD).
    

Detailed Description

      Participants who complete the 48 weeks of treatment in Period 1 will have the option to
      receive ALXN1840 for 24 weeks in Period 2 (open-label extension).

      Safety will be monitored throughout the study.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Percentage Change From Baseline To Week 48 In Non-ceruloplasmin-bound Copper (NCC) In Plasma

Secondary Outcome

 Area Under The Effect Versus Time Curve (AUEC) For NCC And Plasma Total Copper

Condition

Wilson Disease

Intervention

ALXN1840

Study Arms / Comparison Groups

 ALXN1840
Description:  ALXN1840 will be administered at one of two starting doses, with incremental dose increases permitted.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

48

Start Date

October 6, 2021

Completion Date

May 31, 2024

Primary Completion Date

October 31, 2023

Eligibility Criteria

        Key Inclusion Criteria:

          1. Diagnosis of Wilson Disease by Leipzig Score ≥ 4.

          2. Adequate venous access to allow collection of required blood samples.

          3. Able to swallow intact ALXN1840 tablets or mini-tablets.

          4. Willing to avoid intake of foods and drinks with high contents of copper.

          5. Willing and able to follow protocol-specified contraception requirements.

        Key Exclusion Criteria:

          1. Decompensated hepatic cirrhosis or MELD score > 13 (ages 12 to <18) or PELD score > 13
             (ages 3 to < 12).

          2. Modified Nazer score > 7.

          3. Clinically significant gastrointestinal bleed within past 3 months.

          4. Alanine aminotransferase (ALT) > 2 × upper limit of normal (ULN) for participants
             treated for > 28 days with WD therapy or ALT > 5 × ULN for treatment-naïve
             participants or participants who have been treated for ≤ 28 days.

          5. Marked neurological disease requiring either nasogastric feeding tube or intensive
             inpatient medical care.

          6. Hemoglobin less than lower limit of the reference range for age and sex.

          7. History of seizure activity within 6 months prior to informed consent/assent.

          8. Participants in renal failure, defined as in end-stage renal disease on dialysis
             (chronic kidney disease stage 5) or estimated glomerular filtration rate < 30
             milliliters/minute/1.73 meter squared.
      

Gender

All

Ages

3 Years - 17 Years

Accepts Healthy Volunteers

No

Contacts

Eugene S. Swenson, MD, PhD, +1 855-752-2356, [email protected]

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT05047523

Organization ID

ALXN1840-WD-302

Secondary IDs

2021-001015-82

Responsible Party

Sponsor

Study Sponsor

Alexion Pharmaceuticals


Study Sponsor

Eugene S. Swenson, MD, PhD, Study Director, Alexion Pharmaceuticals


Verification Date

June 2022